Member Info for KingHomerJ

Tricky - probably agree - let’s see what happens after crazy hour.

Full Year in Line with expectation which are the highest revenue levels to date.....Along with Loss reduction and actively discussing a number of further contracts....

Lots of news to come....

The 16 Million MC it was 2 years ago is the first step....(Thats 8p per share) that's still cheap as we are way way down the line

* pipeline & Highest revenue to date

* New ADC's contracts & development into VT Tech

* Dosemerx Update

* NHS Trial

*Precision prostate cancer dosing tool (Grant funded)

* Beyond Blood Diagnostics update

* The AI Virtual Tumour platform getting endorsed by Major multi billion £ pharmas....

* FDA stated there is now a requirement for modelling within drug development......

* New Biostats arm of the business launched in November due update & Contracts (which will be the same / if not more revenue that the VT - as stated in the last investors presentation.

*New TR1 Holder

Well Done Dr Pete...

News due……..

Pipeline contracts as per investor presentation (Pipeline 2 Mil plus) Trading Update INLINE

Trading Update (LOSS Reduced)

Dosemerx Update on integration with clinician all over the world....DUE

Plan for dosing tool (JV - separate business arm ) based on commercial pathway...DUE

Another 1 peer review due…..2 already announced - Merck (65 Billion MC) Astellas (17 Billion MC)

Then there’s the new business arm launched in November on Biostats which as per presentation will be significant as this allows us to work on all pre clinical and clinal trials for all phases of drug development across phases 1-4 - all giving the VT platform real life Data in the VT Ai Model....Update Due

Then theirs is the ADCs which is a new field worth multi billions and our first contract already dropped.

The MC should serious rerate - as stated before 3 years ago it was a 16mil MC and we are way way down the line now.

News Flow Rich Period which should drastically increase the MC Significantly ..

And this is just the news we know about.....

2 Peer Reviews within a month with Two Multi Billion Large Pharmas. (17billion & 65 billion)

Great endorsement for the VT platform...with these endorsements this allows PYC to negotiate more and larger contracts.

PM at 15p that would be a MC of £56million I believe.

Agreed Laura……most don’t have the lengthy list of News due (that we know about)

Very much what a lot of us on here have been saying for a lengthy period of time.

I wish him well and everyone that is holding….

The valuation could be much higher but at the same you there is no mention of the costs to get it to these phases. Which can be 100’s millions

10 global biopharmaceutical company by R&D spending estimated that they saved more than half a billion dollars over three years using MIDD to inform key decisions.

https://www.forbes.com/councils/forbestechcouncil/2024/11/27/adoption-of-model-informed-drug-development-can-improve-pharma-roi/

What News????

News due……..

Pipeline contracts as per investor presentation

Dosemerx Update on integration with clinician all over the world

Plan for dosing tool (JV - separate business arm ) based on commercial pathway

Another 2 peer review due…..I’d expect it to be Numab (asset work on bought by J&J for £1.4 Billion) & another Bicycle / Merk / Top Tier Pharma

Then there’s the new business arm launched in November on Biostats which as per presentation will be significant as this allows us to work on all pre clinical and clinal trials for all phases of drug development across phases 1-4 - all giving the VT platform real life Data in the VT Ai Model

Then theirs is the ADCs which is a new field worth multi billions and our first contract already dropped.

The MC should serious rerate - as stated before 3 years ago it was a 16mil MC and we are way way down the line now.

News Flow Rich Period which should drastically increase the MC

If people are investing based on random peoples opinions both positive or negative on a bs message board then frankly they need their heads looking at….

And if you think more people would invest based on this bb being an echo chamber of positivity then your delusional.

While specific commercial valuation figures for the dosing tool are not publicly disclosed, the successful validation and potential regulatory approval could position Physiomics to capture a significant share of the market for personalized chemotherapy dosing solutions. The tool's ability to improve patient outcomes and reduce healthcare costs enhances its attractiveness to healthcare providers and payers, potentially leading to substantial commercial value for Physiomics plc.

Physiomics PLC has developed a Prostate Cancer Dosing Tool as part of its proprietary Virtual Tumour technology. The tool is designed to help in optimizing cancer treatment regimens by simulating how a patient's cancer would respond to various drug doses and combinations. This personalized approach can potentially improve treatment efficacy and minimize side effects, which is crucial for conditions like prostate cancer.

The commercial value of such a tool lies in several key areas:

Personalized Medicine: As the pharmaceutical industry increasingly moves toward more personalized treatments, tools like this can be valuable for tailoring prostate cancer therapies to individual patients. This can lead to better outcomes and more efficient drug development.

Drug Development: The Prostate Cancer Dosing Tool could be instrumental in the clinical trial process, helping pharmaceutical companies optimize dosing strategies early on. This reduces the time and cost involved in developing new prostate cancer drugs.

Partnership Opportunities: By demonstrating its value in improving treatment outcomes, Physiomics could potentially attract partnerships with large pharmaceutical companies or oncology-focused biotechs looking to integrate this tool into their drug development pipelines.

Market Demand for Prostate Cancer Solutions: Prostate cancer remains one of the most common types of cancer worldwide, and there is ongoing demand for more effective treatment options. A tool that enhances the effectiveness of these treatments could be very valuable both commercially and clinically.

Regulatory and Insurance Approvals: If the tool is proven to improve treatment success rates, it could be considered for use in clinical settings, increasing its commercial value. Additionally, insurance companies may reimburse for treatments optimized using the tool, further expanding its potential market.

In summary, Physiomics' Prostate Cancer Dosing Tool has significant commercial potential, especially if it is validated through clinical trials and integrated into existing oncology practices, improving both the development of prostate cancer therapies and personalized treatment regimens.

Tricky - Need another Where are the buyers post lol - see if we can break 1.25 today...

Jaari....

Just before I filter you for your nonsense...

All the information below is in RNS from the past few months and also in the investors presentation...

Don't start posting nonsense without substance...you are frankly lazy and disruptive, if you actually did some research you would realise your comments are baseless

I'm confident you are in no position to question anyone about anything to be honest.

Rather sad life to be honest...

I'm happy with my investment, research and the communications I have with the company and my investments are my decision and my decision solely. (As are everyone elses)

GL & All the best

KHJ

News due……..

Pipeline contracts as per investor presentation

Dosemerx Update on integration with clinician all over the world

Plan for dosing tool (JV - separate business arm ) based on commercial pathway

Another 2 peer review due…..I’d expect it to be Numab (asset work on bought by J&J for £1.4 Billion) & another Bicycle / Merk / Top Tier Pharma

Then there’s the new business arm launched in November on Biostats which as per presentation will be significant as this allows us to work on all pre clinical and clinal trials for all phases of drug development across phases 1-4 - all giving the VT platform real life Data in the VT Ai Model

Then theirs is the ADCs which is a new field worth multi billions and our first contract already dropped.

The MC should serious rerate - as stated before 3 years ago it was a 16mil MC and we are way way down the line now.

Hendrix very much agree….huge block buying….if it’s the same person / company then I’d expect a TR1 as this will well above the threshold

Must be position building as it’s block buying around £120k over the past two days

Looking really strong….

News due……..

Pipeline contracts as per investor presentation

Dosemerx Update on integration with clinician all over the world

Plan for dosing tool (JV - separate business arm ) based on commercial pathway

Another 2 peer review due…..I’d expect it to be Numab (asset work on bought by J&J for £1.4 Billion) & another Bicycle / Merk / Top Tier Pharma

Then there’s the new business arm launched in November on Biostats which as per presentation will be significant as this allows us to work on all pre clinical and clinal trials for all phases of drug development across phases 1-4 - all giving the VT platform real life Data in the VT Ai Model

Then theirs is the ADCs which is a new field worth multi billions and our first contract already dropped.

The MC should serious rerate - as stated before 3 years ago it was a 16mil MC and we are way way down the line now.

Thanks….

Very reassuring especially with the news fly due…

Rerate confirmed…. Rightly so